Please login to the form below

Not currently logged in

CDK4/6 inhibitors

This page shows the latest CDK4/6 inhibitors news and features for those working in and with pharma, biotech and healthcare.

Kisqali combination follows Verzenio onto Cancer Drugs Fund

Kisqali combination follows Verzenio onto Cancer Drugs Fund

The ruling is good news for the company, which is vying with two other treatments in the same CDK4/6 inhibitors class, Eli Lilly’s Verzenio and market leader, Pfizer’s

Latest news

  • Lilly's abemaciclib data leaves potential uncertain Lilly's abemaciclib data leaves potential uncertain

    The trial also threw out some data that could have a bearing on all CDK4/6 inhibitors, namely that around one-third of women may not need a CDK 4/6 ... That view was echoed by Giuseppe Curigliano of the European Institute of Oncology (IEO) in Milan, Italy

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...